ReviewhLife2024
Mucosal vaccine development for respiratory viral infections.
Review in hLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal vaccines have risen to prominence in the corona virus disease 2019 (COVID-19) pandemic due to their ability to elicit both local antibody and tissue-resident T cell responses, affording a dual-layered defense against infection and transmission at respiratory entry sites. While intramuscular vaccines predominantly focus on systemic immunity, mucosal vaccines offer a more nuanced, site-specific approach. However, the field faces a dearth of mucosal vaccine options for respiratory diseases, starkly contrasting to the extensive array of well-characterized injectable vaccines. The unique features of mucosal surfaces necessitate specialized adjuvants and delivery systems, adding complexity to adapting injectable vaccine technologies for mucosal applications. Here, we review the recent insights into the specificities of respiratory mucosal immunology that provide a foundation for future innovations besides the emerging vaccine platforms, newly discovered adjuvants, and vaccine delivery systems, which may open promising avenues for developing mucosal vaccines targeting respiratory pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.